Abstract:This study aims to investigate the potential use of polymer inclusion in the phospholipid-based solid dispersion approach for augmenting the biopharmaceutical performance of Aprepitant (APT). Initially, different polymers were screened using the microarray plate method to assess their ability to inhibit drug precipitation in the supersaturated solution and HPMCAS outperformed the others. Later, the binary (BD) and ternary (TD) phospholipid dispersions were prepared using the co-solvent evaporation method. Solid-state characterization was performed using SEM and PXRD to examine the physical properties, while molecular interactions were probed through FTIR and NMR analysis. In vitro dissolution studies were performed in both fasted and fed state biorelevant media. The results demonstrated a substantial increase in drug release from BD and TD, approximately 4.8 and 9.9 times higher compared to crystalline APT in FaSSIF. Notably, TD also showed a lowered dissolution difference between fed and fasted states in comparison to crystalline APT, indicating a reduction in the positive food effect of APT. Moreover, we assessed the impact of polymer inclusion on permeation under in vitro biomimetic conditions. In comparison with the crystalline APT suspension, both BD and TD demonstrated approximately 3.3 times and 14 times higher steady-state flux (J ss values), respectively. This can be ascribed to the supersaturation and presence of drug-rich submicron particles (nanodroplets) along with the multiple aggregates of drug with phospholipids and polymer in the donor compartment, consequently resulting in a more substantial driving force for passive diffusion. Lastly, in vivo pharmacokinetic evaluation demonstrated the enhanced absorption of both TD and BD over the free drug suspension in the fasted state. This enhancement was evident through a 2.1-fold and 1.3-fold increase in C max and a 2.3-fold and 1.4-fold increase in AUC 0-t , respectively. Overall, these findings emphasize the potential of polymer-based phospholipid dispersion in enhancing the overall biopharmaceutical performance of APT.

Dissolution Improvement of Cisapride by Solid Dispersion with HPMC

Study on pramipexole dihydrochloride sustained-release tablets

Application of HPMC HME polymer as hot melt extrusion carrier in carbamazepine solid dispersion

Carboxymethyl starch as a solid dispersion carrier to enhance the dissolution and bioavailability of piperine and 18β-glycyrrhetinic acid

Preparation of Hot-Melt-Extruded Solid Dispersion Based on Pre-Formulation Strategies and Its Enhanced Therapeutic Efficacy

Improved Dissolution and Solubility Characteristics of Clopidogrel Bisulphate using Gelucire 44/14

Preparation and Characterization of Solid Dispersions of Dipyridamole with a Carrier “copolyvidonum Plasdone®S-630”

Solubility improvement of curcumin by crystallization inhibition from polymeric surfactants in amorphous solid dispersions

Influence of different polymers on crystallization tendency and dissolution behavior of cilnidipine in solid dispersions.

Preparation and in vitro evaluation of curcumin solid dispersions

Evaluation of the effect of carrier material on modification of release characteristics of poor water soluble drug from liquisolid compacts

Improving the Dissolution Rate of Poorly Water Soluble Drug by Solid Dispersion and Solid Solution—Pros and Cons

Evaluation of Carbopol 71G and HPMC As Matrix Materials in a Sustained Release Formulation

Supersaturable diacyl phospholipid dispersion for improving oral bioavailability of brick dust molecule: A case study of Aprepitant

Revaprazan-loaded surface-modified solid dispersion: physicochemical characterization and in vivo evaluation

Enhanced drug release through nitrendipine/hydroxypropyl methylcellulose solid dispersion via supercritical antisolvent technique

Curcumin amorphous solid dispersions benefit from hydroxypropyl methylcellulose E50 to perform enhanced anti-inflammatory effects

In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier.

Preparation and In Vitro/Vivo Evaluation of New Celecoxib Solid Dispersions with Co-Carrier Containing Aerosil and Poloxamer 188

Study on the Preparation and Dissolution of Flupirtine Maleate Solid Dispersions

Impact of HPMCAS on the Dissolution Performance of Polyvinyl Alcohol Celecoxib Amorphous Solid Dispersions